COVID-19 /SARS-CoV2 update
all Reaction Biology research facilities are fully operational under safe work environment guidelines. Our sales staff and business development team are happy to discuss any project with you. Please reach out!
Cooperation with 4HF Biotec to provide new Bioinformatic Cell Service
In cooperation with the bioinformatics firm 4HF Biotec, we announce the offering of a combination of the ProLiFiler cell panel screening service with 4HF‘s bioinformatic evaluation of the drug‘s profile.
ProQinase is now Reaction Biology Europe
ProQinase rebranding into Reaction Biology Europe GmbH was performed completing the process of acquiring ProQinase. As this only represents a change of name, all contracts with former ProQinase remain valid and binding. All ProQinase products and services are continued and available within the Reaction Biology portfolio.
Reaction Biology and Pharmacore Lab announce China outreach
We are pleased to announce a joint collaboration agreement with PharmaCore Labs, a firm located in Haimen, China. PharmaCore Labs will increase our visibility in China with business support and development personnel. We will make our full suite of biochemical, cell-based, and in vivo assay services available to…
Integrated Drug Discovery Project with Bionetix
Bionetix, ProQinase, and MercachemSyncom announce a joint research project from target Identification to clinical study for a new AML drug.
Establishment of advanced oncology profiling cascade with Gotham
Reaction Biology Receives Subcontract for Biophysical Drug Discovery
Reaction Biology has received a subcontract from Leidos Biomedical Research, Inc., which operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute. Under the subcontract, RBC will work on an early stage drug discovery project for the National Cancer Institute’s Experimental…
ProQinase GmbH Purchased by Reaction Biology Corporation
Reaction Biology Announces New NanoBRET Technology in Collaboration with Promega
NanoBRETTM, a new cell based profiling service for drug discovery announced by Reaction Biology Corporation and Promega Corporation will allow more researchers to better prioritize compounds earlier.
Reaction Biology Joins the Fight Against DIPG with M4K Pharma
Reaction Biology Corporation has partnered with M4K Pharma, an open science drug discovery and development company, in the fight against diffuse intrinsic pontine glioma (or DIPG), a rare pediatric brain cancer with no curative therapies.
Reaction Biology launches ion channel division
Reaction Biology Corporation has launched a new division to provide ion-channel discovery services. RBC has completed an acquisition of ion-channel assets from a Pennsylvania-based firm, has retained their senior scientist personnel with decades of electrophysiology experience and has…
ProQinase GmbH is now ISO 9001:2015 certified
ProQinase constantly works on the improvement of the quality of its products, services and customer relationship. Therefore, the company is now officially certified according to DIN EN ISO 9001:2015. The certification represents another milestone in our continued commitment to highest quality standards and customer satisfaction.
New Distributor in China
4A Biotech Co. Ltd. and ProQinase have signed an agreement for distribution of ProQinase’s products in China. 4A Biotech Co. Ltd. has been appointed as exclusive distributor of ProQinase kinase-related products under ProQinase’s brand name in the territory of the PR of China (excluding Taiwan). All Chinese customers interested in ordering such products are kindly requested to contact junyi.li [at] 4abio.com.
Reaction Biology Announces Bromodomain Grant
Reaction Biology Corporation has been awarded a Phase ISBIR grant from the National Center for Advancing Translational Sciences to create tools and techniques for bromodomain drug discovery.
Reaction Biology Receives NIH Grant Award for Epigenetic Database
Reaction Biology Corporation has been awarded a Phase ISBIR grant from the National Center for Advancing Translational Sciences to create a database of epigenetic drug interactions.
Reaction Biology and Cisbio Bioassays Sign Distribution Agreement
Reaction Biology Corporation has signed an agreement for Cisbio Bioassays, a cutting-edge biotechnology company in the field of products and services for human in vitro diagnostics and pharmaceutical research, to distribute its epigenetic proteins.
Reaction Biology Top-Ranked in Kinase Profiling Survey
Reaction Biology Corporation has received the highest number of positive ratings in a recent industry survey.
RBC’s methyltransferases the preferred enzymes for BellBrook Labs’ Transcreener technology
Reaction Biology and BellBrook Labs are working together to make it easier to screen and profile methyltransferases. Reaction Biology has produced more than 30 recombinant human methyltransferases to the most stringent purity and activity requirements in the industry.
Reaction Biology Corporation Announces New Epigenetic Production Facility
Reaction Biology Corporation opens a new protein production facility. The new purpose-built space is situated almost adjacent to RBC’s current drug-screening facilities in the Great Valley Corporate Center in Malvern, Pennsylvania.
Reaction Biology Now Offers Recombinant Methyltransferases to Complement Its Existing Epigenetic Services
Reaction Biology today announced the rollout of a new product line, recombinant proteins for epigenetic research. The initial offerings will emphasize the histone …
Reaction Biology Receives NCI Grant Award for Epigenetic Platform
Reaction Biology Corporation ("RBC") announced today that it has been awarded a Phase I SBIR grant from the National Center for Advancing Translational Sciences to create a database of epigenetic drug interactions.
See the press release here.
ProQinase is part of the German research alliance BioTag to develop new biomarker screens to measure tumor response to innovative protein kinase inhibitors
Proteome Sciences R&D GmbH and Co. KG, Frankfurt, ProQinase GmbH, Freiburg, and the NMI Natural and Medical Sciences Institute, today announced the start of BioTag, a three-year grant project supported by the German Federal Ministry of Research (BMBF) as part of the KMU-Innovative-2 Program, to establish and to validate new workflows for the development and early clinical evaluation of inhibitors targeting tumor protein kinases.
Please read the press release here.
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
CRELUX and ProQinase announced today that they have entered into a joint agreement to supply customers with crystal-grade protein kinases and readily available kinase complex structures.
Read the press release here.
ProQinase will identify novel biomarkers for anti-tumour therapies as member of the EU-research consortium „ANGIOTARGETING - European Consortium for Tumour Angiogenesis Research”
Reliable prediction about the success or failure of new anti-tumor therapies can be provided by so-called biomarkers. Biomarkers are patient characteristics, e.g. presence of specific proteins, of which the amount changes as a result of a therapeutic intervention. Detection of biomarkers in peripheral blood of tumor patients can represent a simple and non-invasive method to determine the success or failure of a given treatment. As part of an EU-funded research program ProQinase, a business division of KTB Tumorforschungsgesellschaft mbH at the Tumorbiology Center Freiburg, will identify novel potential biomarkers.
In January 2007 ProQinase became a partner of the „European Consortium for Tumour Angiogenesis Research“, an integrated project that is funded by the EU with 6 Mio Euro. Aim of the research program is the investigation of mechanisms that control the formation of novel blood vessels in tumors (tumor angiogenesis) and the development of novel therapeutical approaches. Fourteen laboratories from ten countries are participating in the project that is coordinated by the University of Bergen, Norway (http://www.uib.no/med/angiotargeting/).
ProQinase uses its Integrated Technology platform to develop kinase inhibitors and to identify, to develop, and carry-out biomarker assays (www.proqinase.com). The company is today one of the biggest service providers of preclinical technologies in the field of protein kinases. As part of the EU-research project, these resources will be used under the supervision of Dr. Michael Kubbutat (Head Research & Development, ProQinase) for the identification of novel potential biomarkers.
„Identification and development of biomarkers are pivotal for the verification and application of novel therapies in oncology. Biomarkers will allow verification of the mechanism of action and the efficacy of drugs and can help to select the best therapy for the individual patient“, states Kubbutat. „ProQinase offers already several Biomarker-assays for clinical studies, however, for most novel therapies suitable biomarkers are heavily missed. With the help of the EU funding, ProQinase can increase significantly its effort to identify novel biomarkers in cooperation with research groups from academia and industry“.
Reaction Biology Corp Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development
Reaction Biology today announced that it has been awarded a Phase I SBIR grant from the National Institutes of Health to develop its new microarray kinase screening technology for testing compounds in nanoliter reactions. The grant funds the use of Reaction Biology’s DiscoveryDot microarray technology for high throughput screening of kinases.
Please read press release here.
Key Organics Ltd and Reaction Biology Corp Announce New Library Screening Format
Key Organics Ltd. and Reaction Biology Corp. today announced that they have teamed up to provide a new library screening format to customers. Beginning this summer, the entire Key Bionet library of 37,500 diverse drug-like compounds will be offered for "rental" screening on Reaction Biology's DiscoveryDot(TM) platform. For the first time, customers will be able to screen the Key library without having to purchase it outright.
Read the press release here.
ChemDiv, Inc. and ProQinaseGmbH to Partner in Lead Discovery and Preclinical Development in Oncology
ChemDiv, Inc. of San Diego, CA, and ProQinase GmbH of Freiburg, Germany, announced that they have signed an agreement to establish a partnership in the discovery and preclinical development of new kinase inhibitors.
Read the press release here.
Reaction Biology Corporation and Key Organics Ltd Announce Drug Discovery Collaboration
Reaction Biology Corp. and Key Organics Ltd. today announced that they have created a Joint Venture to engage in high throughput drug discovery.
The purpose of the collaboration is to identify a series of compounds with the potential of becoming new drugs with further research, and then to partner or sell the compounds to pharmaceutical companies interested in the selected targets. Key supplies diverse sets of compounds synthesized in-house using classical organic procedures optimized for primary screening of druggable targets. Reaction Biology’s DiscoveryDot™ microarray technology reduces screening volumes to one nanoliter size, allowing large scale screening at low cost.
Please read the press release here.
Reaction Biology Corporation Awarded Phase II SBIR Grant for Drug Discovery
Reaction Biology Corp. today announced that it has been awarded a Phase II SBIR grant from the National Institutes of Health to apply its new DiscoveryDot™ High Throughput Screening technology for drug discovery.
The $750,000 grant originates from the National Institute of Dental and Craniofacial Research and funds the use of RBC’s DiscoveryDot™ microarray technology for high throughput screening of caspases and other proteases. The DiscoveryDot™ technology is capable of screening up to 6,600 individual reactions on a 1-by-3 inch glass slide. The one nanoliter reaction volume used by RBC represents one ten-thousandth the volume of conventional screening systems, and can potentially save millions of dollars on large scale screening campaigns through reagent savings, process costs, and labor reduction.
Caspases play pivotal roles in regulating cell apoptosis and represent targets of significant interest in craniofacial medicine and other areas. RBC’s ability to print large chemical compound libraries in hundreds of replicate copies for caspase and protease screening can accelerate early-stage lead identification at a fraction of the cost of conventional technology.
ProQinase and the University of Duesseldorf receive BMBF-Grant for German-Chinese Research Project for the discovery of novel drugs for the treatment of cancer and viral diseases
ProQinase GmbH at the Tumor Biology Center Freiburg, Germany, and the Institute of Pharmaceutical Biology and Biotechnology at the University of Duesseldorf, Germany, announced the start of a research project for the discovery of novel anti-cancer drugs. In cooperation with the Universities of Beijing and Qingdao, China, the Chinese Academy of Sciences and the Chinese biotech company Pason-Biotech, scientists will isolate natural compounds from Chinese marine organisms, and investigate their usefulness for the treatment of cancer and viral diseases. China offers an immense variety of marine organisms that represent a largely unexplored source for natural compounds with medical potential. The project combines the expertise of the Chinese scientists in the field of marine organisms and natural compound chemistry, the knowledge of the groups of Prof. Peter Proksch and Dr. Rainer Ebel of the University of Duesseldorf in the area of natural compound purification and characterization with the know-how of the biotech companies in the field of drug development for viral infections (Pason Biotech) and cancer (ProQinase). The project will be supported by the German Federal Ministry of Research as part of its “Biotechnology Research and Technology-Programme” with about 1 Mio. Euro in the next three years.
Marine organisms such as sponges, snails, algae, fungi and bacteria represent an approved source for compounds with a medical use for different diseases such as cancer (Ara-C), pain (Conotoxin), and viral diseases (Ara-A). Natural compounds are also used as a starting point for the generation of synthetic drugs such as AZT for the treatment of AIDS. „So far more than 10,000 natural compounds with pharmacological properties have been discovered. However, just a small number of marine organisms have been explored so far, which means that an invaluable potential for novel drugs exists in this area“, Prof. Proksch explains. „The cooperation with our Chinese partners allows us to investigate marine organisms derived from a region that features a huge diversity of unexplored species“. Compounds isolated from these organisms will be characterized in biological test systems with regard to their anti-viral properties by PASON Biotech. At the same time, the compounds will be analyzed by ProQinase for inhibitory properties against protein kinases and, subsequently, in cellular and in in vivo models with respect to their anti-tumoral effects.
Many protein kinases, when deregulated, are linked causally to the formation of human tumors. Inhibitors of protein kinases such as Gleevec and IRESSA are recently approved anti-cancer drugs. „The development of protein kinase inhibitors for the treatment of cancer is just at the very beginning. Due to the diversity of molecular alterations found in human cancers, the lack of efficient and safe drugs for the treatment of the different types of cancer is substantial. In this context the development of protein kinase inhibitors represents a very promising strategy“, states Dr. Michael Kubbutat, Head of Research & Development at ProQinase. „ProQinase works on a novel strategy with the goal to develop drugs that simultaneously block different mechanisms that allow the tumors to grow. Bringing together this novel strategy with the potential of natural compounds of yet unexplored marine organisms could result in the discovery of completely novel drugs“.
MorphoSys Antibodies by Design, ProQinase and Natural and NMI receive BMBF-promotion for Kinome-project
ProQinase GmbH, Freiburg, the NMI Natural and Medical Sciences Institute at the University of Tübingen, and Antibodies by Design, a division of MorphoSys AG, Munich, today announced the start of a joint project which could revolutionize the analysis of all human protein kinases – the human “kinome”.
Please read the press release here.
ProQinase participates in EU FP6Research Program „Protein Kinases –Novel Drug Targets of Post Genomic Era“
ProQinase GmbH has received a grant from the 6th European Framework Program(http://europa.eu.int/comm/research/fp6/index_en.html). The Biotech Company is participating in the “ProKinaseResearch” consortium of 23 partners from eleven countries and is coordinated by the University of Helsinki (www.proteinkinase-research.org). Aim of the research is the development of novel inhibitors of protein kinases. Such substances have applications for the treatment of various diseases such as cancer.
Protein kinases are involved in the regulation of crucial steps in the life cycle of cells, i .e.cell growth, death, and differentiation. Not properly controlled, defective, or hyperactive protein kinases are a common cause for cancer and many other disorders. The sequencing of the human genome has revealed more than 500 genes for protein kinases with often still undefined function, but huge potential for drug development.“Today protein kinase inhibitors are very much in the focus of cancer research, as these substances could arrest or at least slow down the growth of tumors,” explains Dr.Kubbutat, head of the project at ProQinase GmbH. “A very few inhibitors like Gleevec to treat CML (a form of leukemia) are already approved. Still, we are lacking therapeutics for many more kinds of cancer. The EU funding helps substantially to intensify our research on protein kinase inhibitors in collaboration with academic and industrial partners."
4SC and ProQinase collaborate on the discovery of new protein kinase inhibitors for cancer treatment.
4SC AG and ProQinase GmbH announced today a research collaboration to identify a new generation of protein kinase inhibitors as the basis for the development of new anticancer drugs. Protein kinases are key components of the signaling pathways of cells, including those pathways implicated in the development of tumors.
“ProQinase’s expertise in protein kinase research will provide an excellent starting point for the discovery process,” stated Dr. Ulrich Dauer, CEO of 4SC. “Because of these existing validated targets, we believe that this collaboration will quickly advance potential drug candidates through research into clinical trials.”
ProQinase will provide disease-relevant protein kinase targets using its proprietary integrated technology platform, including cell-based assays and in vivo models. 4SC will apply its virtual High Throughput Screening technology, 4SCan® in combination with its medicinal chemistry capabilities. Identified lead candidate drugs will be synthesized and provided to ProQinase for biological screening and pharmacological testing.
“4SC, with its cost and time-saving discovery process, represents an ideal partner to rapidly deliver validated lead drug candidates,’’ said Dr. Christoph Schächtele, Managing Director of ProQinase. “Our close proximity to the Tumor Biology Center in Freiburg will greatly facilitate taking these potential new cancer drugs into clinical trials.”
Under the terms of the agreement, both collaboration partners will equally share the resulting project rights from this collaboration.
ProQinase receives "Freiburg Innovation Award 2002" for its Integrated Technology Platform Protein Kinases
The "Freiburg Innovation Award" is given biannually to companies of the region that feature innovative technologies and products that make them leaders in their respective fields. The jury, consisting of members from science, politics, and finance, reviewed 47 applications and selected three companies for their innovative technologies. ProQinase is the only biotech company receiving this year's award.